Disease recurrence after pathologic response
In this study we aim to gain insight into the mechanisms of immune evasion after initial pathologic response to neoadjuvant immune checkpoint inhibition in macroscopic stage III melanoma by pooling data of the neoadjuvant OpACIN, OpACIN-neo and PRADO trials. Here we used RNAseq data from 21 patients(paired end)
- 29/08/2024
- 3 samples
- DAC: EGAC50000000055
- Technology: Illumina NovaSeq 6000
Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL) general policy
Data is available under reasonable request. All data requests will be reviewed by the NKI IRB and must be supported by the Principal Investigator of the study. The researcher will need to sign a data access agreement with the NKI after approval.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
Study ID | Study Title | Study Type |
---|---|---|
EGAS50000000488 | Exome Sequencing |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.
ID | File Type | Size | Located in | |
---|---|---|---|---|
EGAF50000167968 | fastq.gz | 1.2 GB | ||
EGAF50000168005 | fastq.gz | 1.1 GB | ||
EGAF50000168006 | fastq.gz | 900.1 MB | ||
3 Files (3.2 GB) |